Roche has said it will continue with talks with UK health officials to bring its multiple sclerosis drug Ocrevus to NHS patients with primary progressive disease, after NICE said it was not
Children in England and Wales with a rare inherited disorder causing soft and weak bones can have access to a new therapy after NICE said Kyowa Kirin’s Crysvita can receive regular NHS fund
The European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which is
